(Q37073410)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Maintenance of medically induced remission of Crohn's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

3

Christian Mottet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

8

Florian Froehlich

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

7

Pierre Michetti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

2

Pascal Juillerat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

5

Christian Felley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

6

John-Paul Vader

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1

Jean-Jacques Gonvers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

116-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18239403%20AND%20SRC:MED&resulttype=core&format=json

Maintenance of remission in Crohn's disease

2 January 2020

cites work

1 reference

Management of Crohn's disease in adults

21 January 2018

1 reference

Biologic therapy of inflammatory bowel disease.

21 January 2018

1 reference

A meta-analysis of the role of smoking in inflammatory bowel disease

21 January 2018

1 reference

Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

21 January 2018

1 reference

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease

21 January 2018

1 reference

Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study

21 January 2018

1 reference

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

Low dose steroids and clinical relapse in Crohn's disease: a controlled trial

21 January 2018

1 reference

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

The effectiveness of budesonide therapy for Crohn's disease

21 January 2018

1 reference

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

A controlled trial of azathioprine in Crohn's disease

21 January 2018

1 reference

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients

21 January 2018

1 reference

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

21 January 2018

1 reference

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

21 January 2018

1 reference

Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine

21 January 2018

1 reference

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease

21 January 2018

1 reference

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

21 January 2018

1 reference

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

21 January 2018

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

Natalizumab for active Crohn's disease

21 January 2018

1 reference

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

Long-term tacrolimus: a promising therapeutic approach for Crohn's disease

21 January 2018

1 reference

Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease

21 January 2018

1 reference

Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome

21 January 2018

1 reference

Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study

21 January 2018

1 reference

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease

21 January 2018

1 reference

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

21 January 2018

1 reference

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

21 January 2018

1 reference

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

21 January 2018

1 reference